Werkgroep Cardiologische centra Nederland

LATITUDE - deel A (Completed)

A Phase III outcomes trial that will compare the effects of losmapimod 7.5 mg twice daily (BID) for 12 weeks versus placebo when added to standard of care on the incidence of MACE in subjects with ACS (NSTEMI and STEMI).
Medicine
losmapimod
Population
ASCVD
Phase
III
Starting year
2013
More information
ClinicalTrials.gov

Director of Study

dr. A. Mosterd (Cardioloog)
Amersfoort, Meander Medisch Centrum